Nanox Secures NuvioDx Deal to Deploy FDA-Cleared ARC Systems in U.S. Clinics
Nanox Impact Inc. has secured a distribution deal with NuvioDx LLC to deploy FDA-cleared Nanox.ARC digital tomosynthesis systems across multiple U.S. clinical sites, expanding its channel partner network. The agreement enhances Nanox’s U.S. commercialization strategy by leveraging NuvioDx’s regional market access and operational capabilities.
1. Distribution Agreement Details
Nanox Impact Inc., a U.S. subsidiary of Nano X Imaging Ltd., has entered a distribution agreement with NuvioDx LLC to deploy Nanox.ARC multi-source digital tomosynthesis systems across clinical sites in multiple U.S. states. Under the terms, NuvioDx will leverage its regional market access and operational capabilities to support system deployment and sustained utilization.
2. Strategic Impact and System Features
The FDA-cleared Nanox.ARC system enables 3D imaging at lower cost and reduced radiation dose compared to traditional CT, aligning with Nanox’s strategy to broaden access to diagnostic imaging. This agreement bolsters Nanox’s channel partner network as part of its broader U.S. commercialization framework announced earlier this year.